The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.
Mehrdad Mobasher
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Jane Huang
Employment or Leadership Position - Genentech
Rebecca L. Elstrom
Employment or Leadership Position - Genentech
Mostafa Elhamy
Employment or Leadership Position - Genentech
Coen Bernaards
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Michael J. Hallek
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Peter Hillmen
Honoraria - Roche
Research Funding - Roche
Arnon Philip Kater
Honoraria - Roche Netherlands
Thomas J. Kipps
Consultant or Advisory Role - AbbVie; Celgene; Genentech; Panacea Pharmaceuticals
Research Funding - AbbVie; Genentech
John Francis Seymour
Consultant or Advisory Role - AbbVie; Genentech; Roche
Honoraria - AbbVie; Genentech; Roche
Research Funding - AbbVie; Roche
Other Remuneration - Roche